Vedana Therapeutics Raises $46M Series A Led by Westlake BioPartners and Canaan Partners for Migraine Therapy Development
Vedana Therapeutics, a Seattle-based biotech company focused on migraine prevention therapies, raised $46 million in a Series A funding round. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma.
More: FinSMEs, Puget Sound Business Journal
- FinSMEs: Devplan Raises $2.5M Seed Round Led by AI2 Incubator for AI-Native Product Development
-
Puget Sound Business Journal / Rick Morgan: Seattle Biotech Vedana Therapeutics Raises $46 Million to Develop Injectable Migraine Treatments